Abstract
The past 25 years have seen unprecedented advancements in the area of women's health. A number of events have helped to bring the concerns of women's health to the forefront of medicine but the most significant was the women's health movement, which increased attention to women's health issues and the shortcomings of traditional medical practice and research. The National Institutes of Health, the American Medical Association, and the Office of Research on Women's Health were all instrumental in affecting changes. Large studies are now conducted to gather data on the prevention and treatment of the major causes of death in middle-aged and older women, including cancer and osteoporosis. A number of societies have been established to bring attention to serious shortcomings and unmet needs in women's health research worldwide with the focus on the study of diseases that affect only women and the secondary influence of reproduction on other physiological systems. Thanks to insistent congresswomen, women's health activists, pressure from advocacy groups like the National Women's Health Network and the Public Citizen's Health Research Group, women's health issues have risen to the public awareness.
The market for prescription drugs to treat the constellation of conditions that make up the discipline of women's health has follow right along with the consciousness raising efforts. Since Kalorama's last edition of this study, not only have revenues grown almost across all sectors, but the R&D pipeline has virtually exploded, setting up both great potential for the years ahead and some difficult competitive challenges.
This report provides market size, growth, and share for the following product categories:
- Autoimmune diseases
- Cancer
- Gynecological and Sexually Transmitted Diseases
- Hormones
- Osteoporosis
- Urinary Disorders
Table of Contents
Chapter One: Executive Summary
- Scope and Methodology
- Size and Growth of the Market
- Trends Affecting the Market
- Market Outlook
Chapter Two: Introduction and Overview
- History of Women's Health
- Female Reproductive System
- Hormone Regulation
- Demographics
- Epidemiology
- Autoimmune Disease
- Cancer
- Gynecological Infection and Sexually Transmitted Disease
- Hormone-Related Indications
- Osteoporosis
- Urinary Bladder Disorders
- Lifestyle Patterns
Chapter Three: Autoimmune Diseases
- Overview
- Chronic Fatigue Syndrome
- Treatment
- Fibromyalgia
- Treatment
- Rheumatoid Arthritis
- Treatment
- Scleroderma
- Treatment
- Sjogren's Syndrome
- Treatment
- Systemic Lupus Erythematosus
- Treatment
- Market Size and Growth
- Geographical Market Analysis
- Research and Development
- 406381
- Anergix RA
- Ampligen
- Actemra
- Apilmod
- Arcoxia
- CDP 870
- CTLA 41G
- Denosumab
- Interleukin (IL-1)
- LymphoStat-B
- MabThera
- Milnacipran
- Prestara
- Prexige
- Prograf
- Org 39141
- Riquent
- Veldona
- Competitive Market
Chapter Four: Cancer
- Overview
- Breast Cancer
- Overview
- Treatment
- Cervical Cancer
- Overview
- Treatment
- Endometrial Cancer
- Overview
- Treatment
- Ovarian Cancer
- Overview
- Treatment
- Vaginal Cancer
- Overview
- Treatment
- Market Size and Growth
- Geographical Market Analysis
- Research and Development
- Advexin
- Arzoxifene
- Atamestane
- Avastin
- BrevaRex
- Cervarix
- Combidex
- Edotecarin
- Evista
- Herceptin
- Ixabepilone
- Lapatinib
- Lasofoxifene
- MDX-010
- Myocet
- OvaRex
- Pemtumomab
- Tavocept
- Taxoprexin
- Telcyta
- Temsirolimus
- Tykerb
- Vinorelbine IV
- Xinlay
- XRP 98
- Xytotax
- Yondelis
- Competitive Market
Chapter Five: Gynecological Infections and Sexually Transmitted Diseases
- Overview
- AIDS
- Overview
- Treatment
- Agenerase
- Aptivus
- Combivir
- Crixivan
- Entriva
- Fortovase
- Fuzeon
- Hivid
- Invirase
- Kaletra
- Kivexa
- Lexiva
- Prezista
- Rescriptor
- Reyataz
- Sustiva
- Trizivir
- Truvada
- Viracept
- Viramune
- Bacterial Vaginosis
- Overview
- Treatment
- Cervical Dysplasia
- Overview
- Treatment
- Chlamydia
- Overview
- Treatment
- Condyloma Acuminata
- Overview
- Treatment
- Aldara
- Alferon N Injection
- Condylox
- Gardasil
- Genital Herpes
- Overview
- Treatment
- Zovirax
- Gonorrhea
- Overview
- Treatment
- Hepatitis
- Overview
- Treatment
- Baraclude
- Pelvic Inflammatory Disease
- Overview
- Treatment
- Syphilis
- Overview
- Treatment
- Toxic Shock Syndrome
- Overview
- Treatment
- Yeast Infections
- Overview
- Treatment
- Market Size and Growth
- Geographical Market Analysis
- Research and Development
- Ampligen
- Aplaviroc
- BufferGel
- Carraguard
- Clevudine
- HepeX-B
- Hyphanox
- IFN-alpha Lozenge
- Interferon Alfacon/Ribaviron Combination
- Maraviroc
- Multiferon
- PRO 2000
- Proleukin
- Resiquimod
- SAVVY
- Simplirix
- SPO1A
- Telbivudine
- Ushercell
- Zadaxin
- Competitive Market
Chapter Six: Hormone-Related Disorders
- Overview
- Contraception
- Overview
- Treatment
- Oral Contraceptives
- Depo-Provera
- Birth Control Patch
- Vaginal Ring
- Emergency Contraception and Early Option
- Implant
- Intrauterine Device (IUD)
- Endometriosis
- Overview
- Treatment
- Fibroids
- Overview
- Treatment
- Infertility
- Overview
- Treatment
- Menopause
- Overview
- Treatment
- Menstrual Disorders
- Amenorrhea
- Dysmenorrhea
- Sexual Dysfunction
- Overview
- Treatment
- Market Size and Growth
- Geographical Market Analysis
- Research and Development
- Alista
- Alprox-TD
- Asoprisnil
- Bijuva
- Bio-E-Gel
- BufferGel
- E2/DNG Pill
- Evamist
- FC Patch
- Femprox Cream
- Intrinsa
- LibiGel
- IoGen
- Lybrel
- Menopausal Levonorgestrel System
- NOMAC/E2
- Preven Emergency Contraceptive Kit
- Tanaproget
- Tostrelle
- Competitive Market
Chapter Seven: Osteoporosis
- Overview
- Market Size and Growth
- Geographical Market Analysis
- Research and Development
- Aclasta
- AMG 162
- ALX 1-11
- Arzoxifene
- Banzedoxifene
- Denosumab
- Lasofoxifene (Oporia)
- Livial
- Oral Calcitonin
- Ostarine
- Preos
- S12911
- Competitive Market
Chapter Eight: Urinary Bladder Disorders
- Overview
- Cystitis
- Overview
- Treatment
- Incontinence
- Overview
- Treatment
- Overactive Bladder
- Treatment
- Alternative Treatments
- Interstitial Cystitis
- Overview
- Treatment
- Market Size and Growth
- Geographical Market Analysis
- Research and Development
- Competitive Market
Chapter Nine: Issues and Trends
- Women's Health Initiative
- Perimenopausal Use of Contraceptives
- Fosamax Patents Void in European Market
- Insurance Coverage for Contraceptives
- Oral Contraceptives in Japan
- Ovarian Cancer Test
- New Pap Test Screening Guidelines
- Estrogen Labeling
- Osteoporosis Drug Opportunities in Asia
- OTC Plan B
- Cervical Cancer Vaccines
- Women's Access to Health Care and Insurance
- Issues of Middle-Aged and Older Women
- Possible AIDS Vaccine
Chapter Ten: World Market Summary
- Overview
- Total Market Size and Forecast
- Market Analysis
Chapter Eleven: Competitor Profiles
- Industry Structure and Participants
- Akzo Nobel nv Organon International
- Amgen, Inc.
- AstraZeneca PLC
- Barr Laboratories, Inc.
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- GlaxoSmithKline
- Johnson & Johnson
- Merck & Company, Inc.
- Novartis International AG
- Pfizer, Inc.
- Procter & Gamble Company
- Roche
- Sanofi -Aventis
- Schering AG
- Serono International S.A.
- Wyeth
